Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925244 | 0.89 | HRH3 (0.47) | NR1H2GPR119ESR2HRH3HRH1 | |
| SCHEMBL5181709 | 0.84 | NR1H2 (0.45) | NR1H2GPR119ESR2HRH3NPC1 | |
| SCHEMBL4915892 | 0.83 | HRH3 (0.64) | NR1H2GPR119ESR2HRH3HRH1 | |
| SCHEMBL4915755 | 0.82 | ESR2 (0.52) | NR1H2GPR119ESR2HRH3NPC1 | |
| SCHEMBL4923841 | 0.80 | HRH3 (0.46) | HRH3HRH1CNR2 | |
| SCHEMBL5662905 | 0.79 | NR1H2 (0.44) | NR1H2GPR119ESR2HRH3NPC1 | |
| SCHEMBL5713470 | 0.78 | HRH3 (0.39) | HRH3HRH1CNR2 | |
| SCHEMBL4924488 | 0.78 | HRH3 (0.46) | HRH3HRH1CNR2 | |
| SCHEMBL4914350 | 0.77 | HRH3 (0.49) | HRH3HRH1NPC1RAB9ACNR2 | |
| SCHEMBL4917789 | 0.77 | ESR2 (0.55) | NR1H2GPR119ESR2HRH3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| EP-1735299-A1 | TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097778-A1 | TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | NR1H2 463/4885GPR119 187/4885ESR2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.